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the increased risk of suicide  ideation/
attempts in those who use cannabis. 
Moreover, a longitudinal study found that 
frequent cannabis use (at least several times 
a week) predicted later suicidal ideation in 
susceptible males but not females (12). The 
earlier that this intense use first occurred 
and the higher the frequency of cannabis 
use, faster the susceptible individuals expe-
rienced suicidal thoughts.
Frequent and early cannabis use has 
also been associated with impaired mental 
wellbeing among young individuals (13, 
14), and the risk of developing psychiat-
ric conditions such as psychosis (15) and 
major affective disorders (16). Specifically, 
evidence suggests that cannabis use may 
exacerbate pre-existing conditions such 
as bipolar disorder, and predict negative 
outcomes and psychosocial impairment 
(17, 18). According to longitudinal stud-
ies, the high and frequent use of cannabis 
is also associated with longer recovery times 
for affective conditions, more hospitaliza-
tions, poorer compliance with treatment, 
increased aggression, and poorer response 
to treatment in patients with bipolar disor-
der type I and II (12, 17).
Nevertheless, it is important to note that 
many of the studies investigating associa-
tions between cannabis use and psychiat-
ric conditions are cross-sectional in nature 
and cannot establish a causal relationship 
between the two phenomena (19). Further, 
several studies (20, 21) suggest a bidirec-
tional relationship, as cannabis use variables 
do not solely explain the psychiatric out-
comes observed nor do pre-existing psychi-
atric conditions fully explain the increased 
use of cannabis. Some researchers (22) have 
suggested that individuals with high levels 
IntroductIon: the complexIty of 
cannabIs mIsuse
Cannabis is one of the most common illegal 
psychoactive substance used in European 
countries, in particular among adoles-
cents and young adults (1). It has been 
estimated that almost 55% of adolescents 
aged 15–19 years have used cannabis at least 
once in their lifetime (2), while past year 
use is reported by approximately 30% of 
15–17 year olds and over 47% of those aged 
18–19 years (3).
Cannabis use has been associated with 
several adverse life outcomes including 
unemployment, legal problems, depend-
ence, early school leaving, increased risk 
of developing both psychotic and affective 
disorders (3, 4) together with brain struc-
tural and functional abnormalities (5, 6). 
An association between cannabis use, psy-
chiatric disorders and suicidal behavior has 
also frequently been reported, although the 
exact nature of this link is still poorly under-
stood (4).
Globally, suicide is one of the most com-
mon causes of death among young people 
aged 10–24 years (6% of deaths), exceeded 
only by motor vehicle accidents (10%) (7). 
Over the last decade suicidal behavior has 
increased among adolescents and young 
adults, there has also been a trend toward the 
earlier initiation of cannabis use (8). This 
has led researchers to investigate the associ-
ations between the two factors to determine 
if cannabis use may be considered a factor 
that can trigger suicidal behavior.
Evidence indicates that cannabis use is 
significantly associated with both attempted 
and completed suicides among healthy 
youths (9) and both twin studies (10) and 
case-control comparisons (11) have shown 
of anxiety sensitivity or  hopelessness may be 
more sensitive to the negative  reinforcement 
processes of substance use (i.e., the ability 
of substances to modulate negative affec-
tive states) than non-affected individuals; 
however, some individuals experiencing the 
onset of mania or depression are not more 
likely to report increased cannabis use than 
those not experiencing these disorders (23, 
24). In addition, other authors (25) have 
questioned the hypothesis that individuals 
may use cannabis to self-medicate psychotic 
or depressive symptoms.
In summary, cannabis use may be con-
sidered only as a risk factor, and possibly one 
of a great many that may predict the onset 
or exacerbation of affective disorders and 
suicidal behavior (26). Thus, whether can-
nabis use can trigger psychiatric  disorders 
or only precipitate or exacerbate psychiatric 
conditions in vulnerable individuals, is still 
poorly understood.
affectIve symptoms and 
hopelessness: a possIble 
medIatIng factor?
Depression, and in particular hopelessness, 
are widely recognized as strong predictors 
of suicidal behavior (15, 27–29). Specifically, 
hopelessness has been shown to predict 
completed suicides among psychiatric 
patients after 10–20 years of follow-up (30, 
31), and it is significantly associated with 
both adolescent self-harm and completed 
suicides (32).
Studies have also reported that hopeless-
ness may be a risk factor of substance use 
suggesting that the presence of hopelessness 
could be considered a predictor of substance 
misuse (33, 34). With regard to cannabis use, 
Malmberg et al. (22) found that  adolescents 
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 abnormal  pro- inflammatory cytokines 
levels (42), and/or comorbid symptom 
development (43). We highly recommend 
that the complex interaction between these 
variables is more closely investigated in 
adolescents at risk, in order to understand 
the possible emergence of depression and 
suicide.
However, studies including those inform-
ing the development of this model, should 
be considered in the light of significant 
shortcomings. Many of the studies were 
conducted using cross-sectional designs or 
included retrospective evaluations of life-
time behavior while attempting to predict 
long-term outcome variables or making 
reliable causal inferences. In addition, these 
studies adopted different measurements and 
outcome variables or they assessed patients 
at different time points (for more details see 
a complete list of limitations within Table 1 
in Serafini et al. (15)). Further, not all stud-
ies included specific follow-up periods and 
only some of them were able to distinguish 
between suicide attempts and completions. 
Furthermore, the use of heterogeneous 
samples did not permit some researchers 
to determine a clear association between 
the onset of psychiatric conditions, suicidal 
behavior and the age of first  cannabis use. 
Regarding  retrospective  studies, the absence 
with high levels of hopelessness were more 
likely to have ever smoked cannabis when 
compared to adolescents with lower levels. 
The authors also suggested that increased 
levels of hopelessness were usually associ-
ated with earlier initiation of  cannabis use. 
As such, it is possible that young adolescents 
experiencing hopelessness are more likely to 
use cannabis as a strategy to cope with their 
negative thoughts and feelings (35).
Informed by such research evidence, we 
suggest that the presence of hopelessness 
should be considered as a specific risk factor 
of negative outcome and suicidal behavior 
among depressed individuals with a history 
of early cannabis use. Thus in this review, we 
propose a theoretical model that addresses 
this issue (see Figure 1 for more details). This 
view is consistent with the hypothesis that 
early cannabis use may represent a relevant 
risk factor that can trigger or exacerbate sui-
cidal behavior in vulnerable adolescents and 
young adults, with high hopelessness lev-
els. In addition, vulnerable individuals may 
show hopelessness (36) and risk factors such 
as dysthymic temperamental traits (37, 38), 
dysthymia associated with periventricular 
white matter abnormalities (39), possibly 
the S-allele of the serotonin transporter 
gene polymorphism (5-HTTLPR) (40), 
sleep  disturbances (e.g., insomnia) (41), 
of any strategies to ensure both inter-rater 
reliability and validity of the data also indi-
cates that careful consideration must be 
given to the study results. Finally, the patients 
did not receive psychiatric assessments using 
structured psychometric instruments in all 
studies.
ImplIcatIons for preventIon
Psychological distress and social decline 
need to be carefully investigated in young 
adolescents in order to provide appropriate 
ongoing management (44). Youth suicide 
prevention programs aimed at identify-
ing risk behavior and the subgroups of 
individuals at high suicidal risk are abso-
lutely necessary in clinical practice. Based 
on the current literature, such vulnerable 
subgroups of individuals include those 
who used cannabis early during adoles-
cence (22), those who currently experience 
hopelessness (15), and those at high clini-
cal risk of psychiatric conditions (45–47). 
Furthermore, vulnerable individuals usu-
ally present with additional risk factors 
that may severely influence their childhood 
development [e.g., a poor performance on 
tasks assessing sustained attention, impulse 
control and executive functioning (48)], 
presumably affecting both their suicide risk 
as well as early use of cannabis (12, 22, 44, 
49–51) (for more details see Table 1).
Early warning signs of emerging psy-
chiatric conditions such as behavioral, 
emotional, and cognitive changes, should 
be quickly recognized by clinicians by per-
forming a multi-dimensional assessment 
of the patients (52). In addition, we rec-
ommend the careful assessment of hope-
lessness since it has been demonstrated to 
significantly increase the accuracy of suicide 
risk assessment by allowing the collection 
of reliable information about suicide risk 
even several years after the initial assessment 
(53). We also suggest that clinicians assess 
the current and past use of cannabis in their 
patients, including a determination of the 
age of initial use.
According to the affective model of 
prevention, young adolescents begin to 
use cannabis because they have poor self-
esteem, poor self-control, and poor deci-
sion-making skills (35). In this context, 
youths may also experience negative expec-
tations about their self and their future 
related to depression or pervasive feelings 
of loneliness (54). Prevention programs 
Figure 1 | The complex interaction between risk factors involved in the emergence of suicidal 
behavior: the mediating effect of hopelessness.
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Of particular interest for clinicians is the 
identification of individuals at risk of 
suicide who show early (i.e., prodromal) 
affective symptoms such as hopelessness. 
Suicide prevention programs may provide 
additional benefits if they focus on delaying 
or reducing adolescent cannabis use as well 
as responding to early signs of depression 
and hopelessness, which are widely recog-
nized as important risk factors for suicide 
(58).
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strategies may include actively explaining 
how to implement non-use behavior, such 
as coping skills for prodrug pressures and 
negative affective states, helping youths to 
understand that most people do not use 
cannabis, as well as increasing their aware-
ness of the consequences of cannabis use 
and benefits related to non-use (57). In 
particular, research has demonstrated the 
efficacy of social-influence programs that 
use interactive (not didactic) sessions, and 
those that encourage active participation in 
small groups (55, 56).
In summary, clinicians need to be aware 
of the importance of preventive programs 
that are directed at preventing/treating 
modifiable factors such as adolescent hope-
lessness and/or delaying early cannabis use 
in specific subgroups of adolescents who 
experience major affective disorders.
conclusIon
Suicide, cannabis use, and psychiatric 
 conditions (e.g., depression) are likely to 
be underpinned by similar complex  factors. 
aimed at helping young  adolescents to 
clarify their  subjective states, improve their 
decision-making abilities and enhance 
their self-esteem are available, thus poten-
tially preventing the onset of hopelessness 
and subsequent suicidal ideation (55, 56). 
Young adolescents are expected to per-
ceive the information provided in these 
programs as credible, otherwise they will 
not be likely to modify their behaviors 
(57). These prevention programs should 
be conducted during early adolescence and 
specifically focused on addressing hope-
lessness, although it is currently unclear 
whether the benefits may vary for different 
subgroups of adolescents (e.g., younger or 
older individuals) (57).
Evidence also suggests that school-based 
programs are very effective in preventing 
and/or reducing the use of cannabis among 
young adolescents, especially if they are 
able to provide active motivational strat-
egies that inform adolescents about the 
prejudices against using psychoactive 
medications (55–57). For example, typical 
Table 1 | risk factors for suicide risk and early cannabis use in adolescents.
Socio-demographic Death/loss of a parent or close friend
and social factors Social events including humiliation, loss, defeat, or threat
 Interpersonal problems such as romantic difficulties
 Poor social support
 Financial or employment problems
 Availability of weapons
 Occasional failure at school or in society
Parental and family factors Family history of suicide or suicide attempts
 Family history of violence and aggression
 Parental substance abuse and/or antisocial behavior
 Parental separation or divorce
 An argument with a parent
 Disorganized family environment
 History of physical/sexual abuse as a child or childhood maltreatment
Individual factors Psychiatric disorders such as affective disorders and psychosis
 Sleep disturbances such as insomnia
 Antisocial and conduct problems
 Loneliness
 Impulsivity and poor self-control
 Hopelessness
 Neuroticism
 Victimization
 History of suicide attempts
 Impairments in decisional competence and decision-making skills
 Aggressive threats/fantasies
 Dysthymic temperamental traits
Sources: van Ours et al. (12), Malmberg et al. (22), Beautrais et al. (49), Bridge et al. (50), Berger et al. (44), 
and Reinherz et al. (51).
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